Dolutegravir Plus 2 NRTIs, in Treatment-Naïve HIV-2 Infected Subjects

Summary

Multicenter, single-arm, open-label clinical trial to evaluate the efficacy, the safety and the tolerability of 50 mg dolutegravir once daily (q.d.) given in combination with 2 NRTIs backbone in HIV-2 positive, treatment-naïve subjects.

Timeline

Start

2017-04-05

Primary completion

2019-07-02

Completion

2019-07-02

Publications

• Pacheco P, Marques N, Rodrigues P, Mansinho K, Maltez F, Janeiro N, Franco C, Trigo D, Batista J, Duque L, Lopes MJ, Aleixo MJ, Silva AR, Tavares R, Alves J, Peres S, Povoas D, Lino S, Gomes P, Araujo V, Lopes C. Safety and Efficacy of Triple Therapy With Dolutegravir Plus 2 Nucleoside Reverse Transcriptase Inhibitors in Treatment-Naive Human Immunodeficiency Virus Type 2 Patients: Results From a 48-Week Phase 2 Study. Clin Infect Dis. 2023 Sep 11;77(5):740-748. doi: 10.1093/cid/ciad339.

Drugs

Indications